
On Thursday, Orphazyme released its restructuring plan, stating that potential investors and buyers had already been identified and contacted.
According to Orphazyme’s deputy chair of the board of directors, Bo Jesper Hansen, the number of suitors can be counted on two hands, and the list is mostly comprised of other pharmaceutical and biotech companies.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app